JP2011528656A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528656A5
JP2011528656A5 JP2011518816A JP2011518816A JP2011528656A5 JP 2011528656 A5 JP2011528656 A5 JP 2011528656A5 JP 2011518816 A JP2011518816 A JP 2011518816A JP 2011518816 A JP2011518816 A JP 2011518816A JP 2011528656 A5 JP2011528656 A5 JP 2011528656A5
Authority
JP
Japan
Prior art keywords
drug delivery
delivery system
administered
eye
amd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011518816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528656A (ja
Filing date
Publication date
Priority claimed from US12/176,238 external-priority patent/US8821870B2/en
Application filed filed Critical
Publication of JP2011528656A publication Critical patent/JP2011528656A/ja
Publication of JP2011528656A5 publication Critical patent/JP2011528656A5/ja
Pending legal-status Critical Current

Links

JP2011518816A 2008-07-18 2009-07-13 萎縮性加齢性黄斑変性の処置方法 Pending JP2011528656A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/176,238 2008-07-18
US12/176,238 US8821870B2 (en) 2008-07-18 2008-07-18 Method for treating atrophic age related macular degeneration
PCT/US2009/050373 WO2010009034A2 (en) 2008-07-18 2009-07-13 Method for treating atrophic age related macular degeneration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014169846A Division JP6009511B2 (ja) 2008-07-18 2014-08-22 萎縮性加齢性黄斑変性の処置方法

Publications (2)

Publication Number Publication Date
JP2011528656A JP2011528656A (ja) 2011-11-24
JP2011528656A5 true JP2011528656A5 (enExample) 2012-08-16

Family

ID=41530477

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011518816A Pending JP2011528656A (ja) 2008-07-18 2009-07-13 萎縮性加齢性黄斑変性の処置方法
JP2014169846A Expired - Fee Related JP6009511B2 (ja) 2008-07-18 2014-08-22 萎縮性加齢性黄斑変性の処置方法
JP2016124732A Expired - Fee Related JP6132964B2 (ja) 2008-07-18 2016-06-23 萎縮性加齢性黄斑変性の処置方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014169846A Expired - Fee Related JP6009511B2 (ja) 2008-07-18 2014-08-22 萎縮性加齢性黄斑変性の処置方法
JP2016124732A Expired - Fee Related JP6132964B2 (ja) 2008-07-18 2016-06-23 萎縮性加齢性黄斑変性の処置方法

Country Status (11)

Country Link
US (3) US8821870B2 (enExample)
EP (4) EP3950002A1 (enExample)
JP (3) JP2011528656A (enExample)
KR (1) KR20110047196A (enExample)
CN (2) CN107412778A (enExample)
AU (1) AU2009271168B2 (enExample)
BR (1) BRPI0915981A2 (enExample)
CA (1) CA2731270C (enExample)
ES (3) ES2574706T3 (enExample)
RU (3) RU2668371C2 (enExample)
WO (1) WO2010009034A2 (enExample)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
SG173167A1 (en) 2009-01-29 2011-08-29 Forsight Labs Llc Posterior segment drug delivery
KR20120095371A (ko) * 2009-10-01 2012-08-28 에보닉 데구사 코포레이션 노화 황반변성 치료용 극미립자 조성물들 및 노화 황반변성 치료방법
JP5212849B2 (ja) * 2010-01-14 2013-06-19 株式会社三和化学研究所 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
US20130210876A1 (en) * 2010-01-21 2013-08-15 Allergan, Inc Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
CN102770135A (zh) * 2010-01-21 2012-11-07 阿勒根公司 眼内压降低作用持续时间长的α-2肾上腺素能激动剂
WO2011137363A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
SI2600812T1 (sl) 2010-08-05 2021-12-31 ForSight Vision4, Inc., Naprava za zdravljenje očesa
JP6111194B2 (ja) 2010-08-05 2017-04-05 フォーサイト・ビジョン フォー・インコーポレーテッド 組み合わせ薬物送達方法および装置
SG187730A1 (en) 2010-08-05 2013-03-28 Forsight Vision 4 Inc Injector apparatus and method for drug delivery
CA2808628A1 (en) 2010-08-17 2012-02-23 Ohr Pharmaceutical, Inc. Ophthalmic formulations of squalamine
JP5996544B2 (ja) 2010-10-15 2016-09-21 クリアサイド・バイオメディカル・インコーポレーテッドＣｌｅａｒｓｉｄｅ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ 眼球アクセス用装置
WO2012068549A2 (en) * 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2671589A4 (en) * 2011-02-02 2014-11-19 Public Univ Corp Nagoya City Univ MEDICAMENT FOR PREVENTING OR TREATING DISEASES RELATED TO INTRAOCULAR NEOVASCULARIZATION AND / OR INTRAOCULAR VASCULAR HYPERPERMEABILITY
WO2012149287A1 (en) 2011-04-29 2012-11-01 Allergan, Inc. Solvent cast film sustained release latanoprost implant
HRP20192276T1 (hr) * 2011-06-10 2020-05-15 Ramscor, Inc. Formulacije s produljenim oslobađanjem za dostavu proteina u oko i postupci njihove pripreme
CN103687622A (zh) 2011-06-16 2014-03-26 香港科技大学 含有多个乙烯砜的分子
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
EP3427734B1 (en) * 2011-07-19 2024-07-10 Alternative Extracts Inc. Compositions comprising an anti-angiogenic agent for use in ameliorating symptoms of alzheimer's disease
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc DISPOSAL OF SMALL MOLECULES THROUGH AN IMPLANTABLE THERAPEUTIC DEVICE
LT2755600T (lt) 2011-09-16 2021-04-26 Forsight Vision4, Inc. Skysčio pakeitimo aparatas
WO2013074840A1 (en) * 2011-11-15 2013-05-23 Allergan, Inc. Treatment of dry age related macular degeneration
US10653621B2 (en) * 2012-09-27 2020-05-19 Allergan, Inc. Biodegradable drug delivery systems for the sustained release of proteins
KR102467714B1 (ko) 2012-11-08 2022-11-16 클리어사이드 바이오메디컬, 인코포레이드 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
CN102988301A (zh) * 2012-12-26 2013-03-27 温州医学院 一种含贝伐单抗的长效缓释微球的制备方法
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
WO2014153158A1 (en) 2013-03-14 2014-09-25 Icon Health & Fitness, Inc. Strength training apparatus with flywheel and related methods
BR112015027762A2 (pt) 2013-05-03 2017-08-29 Clearside Biomedical Inc Aparelho e métodos para injeção ocular
US10188550B2 (en) 2013-06-03 2019-01-29 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
EP3016634A2 (en) * 2013-07-05 2016-05-11 Therakine Biodelivery GmbH Drug-delivery composition for topical applications and injections and ophtalmic formulations, method for manufacturing thereof, and methods for delivery a drug-delivery composition
US9782345B2 (en) 2013-10-17 2017-10-10 Jade Therapeutics, Inc. Ocular composition and method
ES2875878T3 (es) 2013-11-18 2021-11-11 Formycon Ag Composición farmacéutica de un anticuerpo anti-VEGF
EP3623020B1 (en) 2013-12-26 2024-05-01 iFIT Inc. Magnetic resistance mechanism in a cable machine
CN106470739B (zh) 2014-06-09 2019-06-21 爱康保健健身有限公司 并入跑步机的缆索系统
RU2710491C2 (ru) 2014-06-20 2019-12-26 Клиасайд Байомедикал, Инк. Устройство для инъекции лекарственного средства в глазную ткань и способ инъекции лекарственного средства в глазную ткань
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP2017524034A (ja) 2014-08-08 2017-08-24 フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法
USD750223S1 (en) 2014-10-14 2016-02-23 Clearside Biomedical, Inc. Medical injector for ocular injection
AU2016224843B2 (en) * 2015-02-26 2019-12-05 Feramda Ltd. Compositions and combinations for the treatment of angiogenesis diseases and disorders
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
WO2016159652A1 (ko) 2015-03-31 2016-10-06 일동제약주식회사 조직투과성 펩타이드와 항-혈관 내피세포 성장인자 제제가 융합된 융합단백질을 유효성분으로 포함하는 안질환 예방 및 치료용 약학적 조성물
EP3305304A4 (en) * 2015-05-29 2019-01-23 Seikagaku Corporation COMPOSITION WITH GLUCOSAMINATE SCANDERIVATE AND CHEMOKIN RECEPTOR ACTIVITY CONTROLLER
US10953305B2 (en) 2015-08-26 2021-03-23 Icon Health & Fitness, Inc. Strength exercise mechanisms
US10940360B2 (en) 2015-08-26 2021-03-09 Icon Health & Fitness, Inc. Strength exercise mechanisms
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
US10072075B2 (en) 2015-09-23 2018-09-11 Genentech, Inc. Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CA3013922A1 (en) * 2016-02-08 2017-08-17 The Johns Hopkins University Dendrimer-bioadhesive polymer hydrogel nanoglue and use thereof
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
CN109073660B (zh) * 2016-02-29 2022-10-28 麦恩泰科特有限公司 可用于治疗湿性年龄相关性黄斑变性的预测性标志物
JP6664115B2 (ja) * 2016-03-15 2020-03-13 原　英彰 アフリベルセプトによる網膜保護作用
US10293211B2 (en) 2016-03-18 2019-05-21 Icon Health & Fitness, Inc. Coordinated weight selection
US10441840B2 (en) 2016-03-18 2019-10-15 Icon Health & Fitness, Inc. Collapsible strength exercise machine
CA3062845A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
US10252109B2 (en) 2016-05-13 2019-04-09 Icon Health & Fitness, Inc. Weight platform treadmill
JP6944958B2 (ja) * 2016-05-25 2021-10-06 参天製薬株式会社 持続性浮腫を伴う滲出性加齢黄斑変性の処置のためのシロリムスの使用
CN110177527B (zh) 2016-08-12 2022-02-01 科尼尔赛德生物医学公司 用于调节药剂递送用针的插入深度的装置和方法
US10661114B2 (en) 2016-11-01 2020-05-26 Icon Health & Fitness, Inc. Body weight lift mechanism on treadmill
US11123411B2 (en) * 2016-12-08 2021-09-21 Gary E. Borodic Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
AR111190A1 (es) 2017-03-22 2019-06-12 Genentech Inc Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados
WO2018201007A2 (en) 2017-04-27 2018-11-01 The Johns Hopkins University Dendrimer compositions for use in angiography
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
KR102101969B1 (ko) * 2017-09-06 2020-04-22 (주)인벤티지랩 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법
CN111615528A (zh) 2017-11-10 2020-09-01 约翰霍普金斯大学 树枝状聚合物递送系统和其使用方法
CN115607358A (zh) 2017-11-21 2023-01-17 弗赛特影像4股份有限公司 用于可扩展端口递送系统的流体交换装置及使用方法
CN108030783A (zh) * 2017-12-27 2018-05-15 广东众生药业股份有限公司 乐伐替尼在制备防治黄斑变性的药物中的用途
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CN112543645A (zh) * 2018-04-17 2021-03-23 前瞻疗法公司 用于治疗疾病的贝伐珠单抗的缓冲制剂
KR102192768B1 (ko) * 2018-12-07 2020-12-18 전북대학교산학협력단 식나무 추출물을 포함하는 황반변성의 예방 또는 치료용 약학적 조성물
DE102019112917B4 (de) * 2019-05-16 2021-07-22 Carl Zeiss Meditec Ag Ophthalmologisches Implantat zur Verwendung bei der Behandlung einer Augenkrankheit und Implantationswerkzeug mit einem solchen ophthalmologischen Implantat
CN109966243A (zh) * 2019-05-17 2019-07-05 上海第二工业大学 一种用于眼底黄斑治疗的释药型凝胶及其制备方法
EP3989982A4 (en) 2019-06-27 2023-06-28 University Of Florida Research Foundation, Incorporated Enhancing aav-mediated transduction of ocular tissues with hyaluronic acid
KR20220036946A (ko) 2019-06-27 2022-03-23 레이어바이오 인크. 안구 장치 전달 방법 및 시스템
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115066232B (zh) 2020-02-06 2024-12-10 视尔普斯眼科公司 用于治疗眼病的组合物和方法
HRP20230800T1 (hr) 2020-03-25 2023-10-27 Ocular Therapeutix, Inc. Očni usadak koji sadrži inhibitor tirozin kinaze
US20230248689A1 (en) * 2020-06-26 2023-08-10 Purdue Research Foundation Pharmaceutical formulations of griseofulvin for long-term ocular delivery
US20240058308A1 (en) * 2021-01-12 2024-02-22 The Regents Of The University Of Michigan Treatment and prevention of dry macular degeneration
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
KR20260002666A (ko) 2023-04-11 2026-01-06 오큘라 테라퓨틱스, 인코포레이티드 악시티닙 다형체 iv를 포함하는 안구 임플란트

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2446405A (en) 1945-10-31 1948-08-03 Hazeltine Research Inc Tunable ultra high frequency resonator system
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5264188A (en) 1991-01-22 1993-11-23 Phillips Petroleum Company Multi-stage hydrotreating process and apparatus
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
WO2000045835A1 (en) * 1999-02-08 2000-08-10 Human Genome Sciences, Inc. Vascular endothelial growth factor-2
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
HK1049438B (en) 1999-10-21 2005-08-26 Alcon, Inc. Sub-tenon drug delivery
US20040229960A1 (en) 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
RU2354398C2 (ru) * 2001-07-13 2009-05-10 Оксиджин, Инк. Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний
KR20050047118A (ko) 2002-09-18 2005-05-19 알러간, 인코포레이티드 안과 임플란트의 수송을 위한 방법 및 장치
CA2504024A1 (en) * 2002-10-31 2004-05-21 Celgene Corporation Composition for the treatment of macular degeneration
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060182781A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244471A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
EP1853259A1 (en) * 2005-02-09 2007-11-14 Macusight, Inc. Formulations for ocular treatment
CN101180086A (zh) * 2005-04-08 2008-05-14 苏尔莫迪克斯公司 用于经视网膜下递送的持续释放植入物
DOP2006000195A (es) * 2005-09-07 2017-08-15 Amgen Fremont Inc Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US8877229B2 (en) * 2005-12-02 2014-11-04 Eyetech Inc. Controlled release microparticles
US20090221684A1 (en) * 2005-12-22 2009-09-03 Trustees Of Boston University Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof
EP1988889A4 (en) * 2006-01-26 2009-07-22 Acucela Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHAMAL DISEASES AND DISORDERS
AU2007247426B2 (en) 2006-05-04 2012-03-08 Fondation Ophthalmologique Adolf De Rothschild Combination comprising a VEGF inhibitor and a serine protease for treating neovascular diseases
CA2662140A1 (en) * 2006-08-31 2008-03-06 Abraxis Bioscience, Llc Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20100111963A1 (en) 2006-11-10 2010-05-06 Genentech, Inc. Method for treating age-related macular degeneration
EP2102165A2 (en) * 2006-11-24 2009-09-23 AC Immune S.A. N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
US20080125377A1 (en) * 2006-11-28 2008-05-29 Bartels Stephen P Delivery system for antiangiogenic and antiinflammatory pharmaceuticals and method of use
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CA2968112C (en) 2016-05-26 2025-09-23 Op-Hygiene Ip Gmbh MAINTENANCE OF A DISPENSER INTENDED FOR AN INSTALLATION WITH MULTIPLE BATHROOMS
US11676102B2 (en) 2019-05-23 2023-06-13 Capital One Services, Llc Searchable index encryption

Similar Documents

Publication Publication Date Title
JP2011528656A5 (enExample)
JP6700348B2 (ja) 持続型薬物送達インプラント
RU2018133133A (ru) Способ лечения атрофической возрастной макулярной дегенерации
JP2008540552A5 (enExample)
JP2010526780A5 (enExample)
US20240082150A1 (en) Ocular compositions
JP2018500394A5 (enExample)
AU2010298480B2 (en) Injectable aqueous ophthalmic composition and method of use therefor
RU2672596C2 (ru) Биологически разлагаемые или биологически разрушаемые микросферы или микрочастицы длительного высвобождения, суспендированные в затвердевающем депообразующем инъекцируемом лекарственном составе
Goyal et al. Current nanotechnological strategies for treating glaucoma
JP2007535552A5 (enExample)
RU2017123358A (ru) Составы на основе сунитиниба и способы их применения для лечения глазных заболеваний
JP2017537985A5 (enExample)
JP2009535422A5 (enExample)
JP2012521997A5 (enExample)
BRPI0708622A2 (pt) terapia ocular usando agentes que ativam a sirtuina
JP2007535564A5 (enExample)
CN103990185B (zh) 一种卡拉胶和明胶微球栓塞剂及其制备方法
Gavini et al. Biodegradable microspheres as intravitreal delivery systems for prolonged drug release. What is their eminence in the nanoparticle era?
Mittal et al. Recent advancemnts in biodegradable ocular implants
JP2013523748A5 (enExample)
WO2005018608A1 (ja) 微粒子テノン嚢下投与ドラッグデリバリーシステム
AU2019408549A1 (en) Ocular compositions
JP2005132737A (ja) 埋込型製剤の薬物保持担体
RU2021117158A (ru) Улучшенные агрегированные микрочастицы